MTOR and primitive neuroectodermal tumor: Everolimus (an mTOR inhibitor) and sunitinib (a VEGF receptor tyrosine kinase inhibitor) were shown in phase III trials to significantly prolong PFS in metastatic PNET, establishing these drugs as standard options.